• A
  • A
  • A
日本語 Help
Science and technology information site for articles, patents, researchers information, etc.
Rchr
J-GLOBAL ID:202001003241547790   Update date: Feb. 05, 2025

Suzuki Hiroyuki

スズキ ヒロユキ | Suzuki Hiroyuki
Affiliation and department:
Research field  (1): Radiology
Research keywords  (2): 分子イメージング ,  放射性薬剤
Research theme for competitive and other funds  (8):
  • 2022 - 2025 悪性黒色腫の標的α線治療を指向するAt-211標識薬剤開発
  • 2023 - 2025 がんの標的アルファ線治療への応用を指向する生体内安定な211At標識法の開発
  • 2023 - 2023 悪性黒色腫に対する標的α線治療の実現性を向上するAt-211標識基盤技術の改良
  • 2019 - 2022 Development of At-211-labeled agents targeting the tumor hypoxia region
  • 2018 - 2021 Development of a versatile alpha particle therapy using At-211 labeled amino acids with controlled pharmacokinetics
Show all
Papers (34):
  • Zhao-Hui Jin, Mélissa Degardin, Takako Furukawa, Tomoya Uehara, Atsushi B. Tsuji, Hiroyuki Suzuki, Hidekatsu Wakizaka, Aya Sugyo, Winn Aung, Hisashi Suzuki, et al. Evaluation of the Gly-Phe-Lys Linker to Reduce the Renal Radioactivity of a [64Cu]Cu-Labeled Multimeric cRGD Peptide. ACS Omega. 2025
  • Hiroyuki Suzuki, Saki Yamashita, Shoko Tanaka, Kento Kannaka, Ichiro Sasaki, Yasuhiro Ohshima, Shigeki Watanabe, Kazuhiro Ooe, Tadashi Watabe, Noriko S. Ishioka, et al. An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging. 2025
  • Status of Development of Short-Range Radionuclide Therapeutic Agents. RADIOISOTOPES. 2024. 73. 3. 271-290
  • Kei Yaginuma, Kazuhiro Takahashi, Seiji Hoshi, Taiki Joho, Saki Shimoyama, Naoko Hasegawa, Koki Hasegawa, Songji Zhao, Naoyuki Ukon, Syunta Makabe, et al. Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model. European Journal of Nuclear Medicine and Molecular Imaging. 2024
  • Muchtaridi Muchtaridi, Wiwit Nurhidayah, Taufik Fakih, Kento Kannaka, Hiroyuki Suzuki, Toto Subroto, Tomoya Uehara. Investigation of a Radio-Iodinated Alpha-Mangostin for Targeting Estrogen Receptor Alpha (ERα) in Breast Cancer: In Silico Design, Synthesis, and Biological Evaluation. Drug Design, Development and Therapy. 2024
more...
MISC (13):
  • Kazuma Sugahara, Kento Kannaka, Hiroyuki Suzuki, Kazuhiro Takahashi, Tomoya Uehara. Development of At-211-labeled cancer therapeutic compounds targeting fibroblast activation protein. 2024. 65. supplement 2. 241771
  • Hiroyuki Suzuki, Rikako Madokoro, Kouki Tatsugi, Masato Matsukawa, Kento Kannaka, Tomoya Uehara. 111In-labeled MC1R-targeting peptide with a renal brush border enzyme-cleavable linkage for low renal radioactivity levels. Journal of Nuclear Medicine. 2023. 64. supplement 1. 549
  • 鈴木 博元, 甘中 健登, 上原 知也. がんの特徴を標的とする核医学治療. ファルマシア. 2023. 59. 12. 1085-1089
  • Hiroyuki Suzuki, Yuta Kaizuka, Maho Tatsuta, Hiroshi Tanaka, Nana Washiya, Yoshifumi Shirakami, Kazuhiro Ooe, Atsushi Toyoshima, Tadashi Watabe, Takahiro Teramoto, Ichiro Sasaki, Shigeki Watanabe, Noriko S Ishioka, Jun Hatazawa, Tomoya Uehara, Yasushi Arano. Neopentyl glycol as a scaffold to provide radiohalogenated theranostic pairs of high in vivo stability. RIKEN Accelerator Progress Report 2021. 2021. 55. 137
  • Tomoya Uehara, Shota Kise, Hiroyuki Suzuki, Yasushi Arano. Development of Cu-64 labeling agent for low molecular weight peptides to reduce renal radioactivity level. Journal of Nuclear Medicine. 2020. 61. supplement 1. 1080
more...
Patents (5):
Lectures and oral presentations  (7):
  • Development of in vivo stable 211At-labeled agents for effective targeted alpha therapy of cancers
    (2024)
  • A novel approach to produce astatine-211-labeled agents for effective and safe targeted alpha therapy.
    (The 4th CRI-CGI-Chiba symposium in Chemistry and Biomedical Sciences 2024)
  • Reduction of renal radioactivity levels of 111In-labeled antibody fragments.
    (The 3rd CRI-CGI-Chiba Symposium in Chemistry 2023)
  • 非特異的な正常組織への集積を低減する放射性薬剤の開発
    (第19回次世代を担う若手のためのフィジカル・ファーマフォーラム(PPF2022) 2022)
  • 腎放射活性の低減に向けた111In標識抗体フラグメントの開発とリシン同時投与の併用
    (第16回日本分子イメージング学会総会・学術集会 2022)
more...
Education (3):
  • 2010 - 2013 Chiba University Graduate School of Medical and Pharmaceutical Sciences
  • 2008 - 2010 Chiba University Graduate School of Medical and Pharmaceutical Sciences
  • 2004 - 2008 Chiba University Faculty of Pharmaceutical Sciences
Professional career (1):
  • (BLANK) (Chiba University)
Work history (2):
  • 2015/01 - 現在 Chiba University Graduate School of Pharmaceutical Sciences
  • 2013/04 - 2014/12 日本原子力研究開発機構 量子ビーム応用研究部門 博士研究員
Awards (4):
  • 2024/11 - 日本核医学会 第21回日本核医学会研究奨励賞 最優秀賞
  • 2024/03 - コニカミノルタ画像科学奨励賞
  • 2022/03 - 日本薬学会 物理系薬学部会 奨励賞
  • 2014/06 - 第15回放射線プロセスシンポジウム ポスターセッション優秀賞
Association Membership(s) (3):
日本分子イメージング学会 ,  日本核医学会 ,  日本薬学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page